Osteoporosis
Samsung Bioepis announces launch of two new denosumab biosimilars in Europe
December 4, 2025Sales and Marketing Oncology, Osteoporosis, Samsung Bioepis
Samsung Bioepis has announced the European launch of Obodence and Xbryk, two new denosumab biosimilars approved for the treatment of …
Sandoz launches two new bone disease biosimilars in Europe
December 3, 2025Sales and Marketing Oncology, Osteoporosis, Sandoz
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 mg) is approved for the …
Healing the fracture in the system: the case for universal fraction liaison services access
November 28, 2025Medical Communications, Research and Development Osteoporosis
By Tina Backhouse In 2024, the UK government committed to achieving 100% coverage of Fracture Liaison Services (FLS)across the NHS …
Biocon Biologics gains EU approval for bone health therapies
July 4, 2025Market Access, Medical Communications, Research and Development Biocon Biologics, Committee for Medicinal Products for Human USE, European Commission, Evfraxy, Oncology, Orthopaedics, Osteoporosis, Vevzuo, bone health, osteoporosis, prostate cancer
Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab biosimilars, Vevzuo and Evfraxy, marking …
Allegro confirms successful safety testing of osteoarthritis treatment
April 17, 2025Research and Development Allegro, Osteoporosis, joint disease, oesteoarthritis, pretrial
Allegro’s hydrocelin treatment for osteoarthritis has demonstrated a satisfactory safety profile, giving it potential to become a leading disease-modifying treatment …
Rani Therapeutics’ oral ‘robotic pill’ delivers injection trans-enterically
June 19, 2023Medical Communications Osteoporosis, Rani Therapeutics, injection, osteoporosis, robotic pill, robotics
US Rani Therapeutics, a clinical-stage biotherapeutics company, has reported new results from its phase 1 trial into the RaniPill capsule …
